NeuroMetrix, Inc. (Nasdaq: NURO) today reported that Michael MacDonald has been promoted to SVP and General Manager of Diagnostics. In this role, Mr. MacDonald will oversee the Company’s diagnostic products which include DPNCheck® and ADVANCE™.

Mr. MacDonald has been with NeuroMetrix for over 15 years, most recently as SVP of Commercial Operations. In this role, he has been responsible for the DPNCheck business in the Americas, Europe, Middle East and India. Prior roles included Vice President of Marketing, Vice President of Healthcare Economics, Director of Marketing and Region Sales Manager. Mr. MacDonald holds a B.S. degree in Business Administration from Northeastern University.

"Diabetes is a world-wide epidemic that now affects over 300 million people. DPNCheck is a unique product with an important role in the early detection of diabetic neuropathy, which is most common long term complication of diabetes and the primary trigger for foot ulcers and lower limb amputations," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "Under Mike’s leadership we have built our DPNCheck business to include a robust Medicare Advantage business in the U.S., growing sales in Mexico, and emerging opportunities in the Middle East and other markets. These opportunities complement our partnership with Omron Healthcare in Japan and China. In this expanded role, Mike will become involved in all aspects of our DPNCheck business as well as continue to manage our legacy ADVANCE diagnostics business.”

About DPNCheck

DPNCheck is a rapid, accurate and quantitative point-of-care test to detect diabetic peripheral neuropathy, or DPN, at an early stage allowing physicians to select appropriate treatment. DPN is the most common complication of diabetes, affecting over half of people with diabetes. It causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations. DPNCheck is marketed in the U.S. to Medicare Advantage providers for profiling their patient population well as guiding treatment. It is distributed in Japan, China, Mexico, the Middle East and other markets in collaboration with various partners. For product information visit DPNCheck.com.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell®, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit NeuroMetrix.com.

NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief Financial Officerneurometrix.ir@neurometrix.com

NeuroMetrix (NASDAQ:NUROW)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025 NeuroMetrix 차트를 더 보려면 여기를 클릭.
NeuroMetrix (NASDAQ:NUROW)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025 NeuroMetrix 차트를 더 보려면 여기를 클릭.